Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14284046 | 0.85 | PTGS2 (0.41) | PTGS2PTGS1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4974334 | 0.84 | ALDH1A1 (0.35) | ADAM17PTGS2PTGS1ALDH1A1CYP3A4 | |
| SCHEMBL4974262 | 0.82 | ENPP2 (0.37) | ADAM17PTGS2PTGS1ALDH1A1CYP3A4 | |
| SCHEMBL4978273 | 0.82 | PTGS2 (0.36) | ADAM17PTGS2PTGS1ALDH1A1CYP3A4 | |
| SCHEMBL4980319 | 0.81 | PTGS2 (0.42) | ADAM17PTGS2PTGS1ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL4980230 | 0.81 | PTGS2 (0.35) | ADAM17PTGS2PTGS1ALDH1A1CYP3A4 | |
| SCHEMBL4973448 | 0.80 | PTGS2 (0.35) | ADAM17PTGS2PTGS1ALDH1A1CYP3A4 | |
| SCHEMBL27676118 | 0.79 | MAOB (0.34) | PTGS2PTGS1 | |
| SCHEMBL27676119 | 0.78 | PTGS1 (0.32) | PTGS2PTGS1 | |
| SCHEMBL5503955 | 0.77 | LMNA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| EP-1761491-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006001752-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | ADAM17 2538/4885PTGS2 1175/4885PTGS1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.